Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Rating Lowered by StockNews.com

Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by equities research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Saturday.

Separately, Cantor Fitzgerald reissued a “neutral” rating and set a $36.00 price objective on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

Supernus Pharmaceuticals Stock Performance

Shares of Supernus Pharmaceuticals stock opened at $32.07 on Friday. The stock has a 50 day moving average of $36.80 and a 200 day moving average of $35.28. The firm has a market capitalization of $1.79 billion, a price-to-earnings ratio of 29.97 and a beta of 0.90. Supernus Pharmaceuticals has a fifty-two week low of $25.53 and a fifty-two week high of $40.28.

Insider Activity at Supernus Pharmaceuticals

In other news, SVP Jonathan Rubin sold 927 shares of Supernus Pharmaceuticals stock in a transaction on Friday, February 21st. The stock was sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the sale, the senior vice president now directly owns 7,853 shares of the company’s stock, valued at approximately $307,444.95. The trade was a 10.56 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Padmanabh P. Bhatt sold 9,477 shares of the stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total value of $376,236.90. Following the transaction, the vice president now directly owns 10,149 shares in the company, valued at approximately $402,915.30. The trade was a 48.29 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 11,104 shares of company stock worth $440,263. Insiders own 9.30% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Raiffeisen Bank International AG purchased a new position in Supernus Pharmaceuticals in the 4th quarter valued at approximately $25,000. GF Fund Management CO. LTD. acquired a new stake in shares of Supernus Pharmaceuticals in the fourth quarter valued at $42,000. Smartleaf Asset Management LLC boosted its holdings in Supernus Pharmaceuticals by 219.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 870 shares during the period. Mark Sheptoff Financial Planning LLC acquired a new position in Supernus Pharmaceuticals during the 4th quarter worth $52,000. Finally, Headlands Technologies LLC increased its holdings in Supernus Pharmaceuticals by 203.0% during the 4th quarter. Headlands Technologies LLC now owns 1,515 shares of the specialty pharmaceutical company’s stock worth $55,000 after purchasing an additional 1,015 shares during the period.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.